The company PFE.N in September agreed to lower prescription drug prices for American patients, including discounts of up to 85% through TrumpRx.gov.
Pfizer said the majority of its primary care treatments and some select brands, such as rheumatoid arthritis drug Xeljanz, dermatitis drug Eucrisa and post-menopausal osteoporosis medicine Duavee, will be offered at average savings of 50%, which can be as high as 85%.
Johnson & Johnson
Drugmaker J&J JNJ.N in January agreed to lower drug prices for American patients, including through the TrumpRx.gov platform.
Specific terms of the agreement were not disclosed, including details on revised drug prices or which medicines are covered.
AstraZeneca
AstraZeneca AZN.L in October agreed to lower prescription drug prices for American patients, including discounts of up to 80% through TrumpRx.gov.
Novo Nordisk
Weight-loss drug maker Novo Nordisk NOVOb.CO in November agreed to reduce prices for its semaglutide medicines, including Wegovy and Ozempic, for American patients through the government's Medicare, Medicaid, and a direct-to-patient cash channel.
Prices of Ozempic and Wegovy will fall from $1,000 and $1,350 per month, respectively, to $350 when purchased through TrumpRx.
Novo Nordisk will also provide widely-used insulin products, including NovoLog and Tresiba, at $35 per month through TrumpRx.
Eli Lilly
Eli Lilly LLY.N in November agreed to offer Medicare beneficiaries its obesity medicines Zepbound and orforglipron, branded as Foundayo, at no more than $50 per month, with additional discounts for self-pay patients through LillyDirect.
The Zepbound multidose pen will be available at $299 per month at the lowest dose, with additional doses priced up to $449, while Foundayo will be available starting at $149 per month at its lowest dose through LillyDirect.
Lilly will also offer Emgality, a migraine treatment, at $299 per pen, and Trulicity, a diabetes medicine, at $389 per month through TrumpRx.
AbbVie
AbbVie ABBV.N in January agreed to lower drug prices through Medicaid and expand direct-to-patient offerings via TrumpRx for medicines, including Humira and Synthroid.
Bristol Myers Squibb
Bristol Myers Squibb BMY.N said in December it will provide its blockbuster blood-thinner Eliquis to Medicaid for free as part of its deal with the Trump administration.
It also agreed to donate more than seven tons of active pharmaceutical ingredient for Eliquis.
Gilead Sciences
Gilead Sciences GILD.O said in December it will provide select medicines to treat HIV, hepatitis C, hepatitis B and COVID-19 at a discounted price for Medicaid beneficiaries.
It agreed to price future medicines at parity with other key developed nations and make its hepatitis C treatment, Epclusa, available at a discounted cash price through TrumpRx and its own direct-to-patient program.
EMD Serono
Trump and Merck KGaA MRCG.DE unit EMD Serono said in October the German company would sell its fertility treatments, including Gonal-f, Ovidrel and Cetrotide, directly to consumers with a combined discount of 84% off list price if three of them were used in IVF.
It would offer all new drugs launched in the U.S. at the prices it charges in other developed countries.
Merck
U.S. drugmaker Merck MRK.N in December said it will sell its diabetes drugs Januvia, Janumet and Janumet XR - set to face generic competition next year - directly to U.S. consumers at about 70% off list prices.
If approved, its experimental cholesterol drug enlicitide will also be offered through direct-to-consumer channels, including TrumpRx.
Roche
Roche ROPC.S unit Genentech said in December it would lower prices for many of its medicines under Medicaid comparable to those available in other wealthy countries.
It also agreed to make its influenza medicines available through TrumpRx.gov and through its own direct-to-patient program.
Novartis
Novartis NOVN.S said in December it would launch new drugs in the U.S. at prices comparable to other developed countries.
It also agreed to make multiple sclerosis drug Mayzent as well as cancer drugs Rydapt and Tabrecta available through its direct-to-patient platform and TrumpRx.gov.
Amgen
Amgen AMGN.O said it will add cholesterol drug Repatha at a monthly price of $239, migraine drug Aimovig, and arthritis treatment Amjevita at $299 a month to its direct-to-patient program, which is 60% to 80% off list price.
Sanofi
Sanofi SASY.PA said in December it will offer lower-cost medicines via TrumpRx and other direct-to-patient platforms, with average savings of about 70% on treatments for infections, heart disease, and diabetes.
It also agreed to align the Medicaid price of several medicines with those in other high-income countries.
GSK
GSK GSK.L in December agreed to make most of its inhaled respiratory medicines and other drugs available to patients on a direct-to-patient platform with savings of up to 66%.
It also agreed to lower the price of certain medicines in Medicaid and launch new drugs with a "more balanced pricing approach" across developed nations.
Boehringer Ingelheim
Boehringer Ingelheim said in December it would make its medicines available through TrumpRx.gov at discounted prices.
Regeneron
Regeneron REGN.O in April agreed to cut prices on its existing and future medicines sold through Medicaid and to lower the price of its cholesterol drug Praluent to $225 from $537 for patients buying directly through TrumpRx.
It will also offer its newly approved gene therapy for a rare form of hearing loss, Otarmeni, for free to eligible U.S. patients.
Midcaps and smaller drugmakers
Astellas
Japan's Astellas 4503.T agreed to lower Medicaid drug prices in line with other developed countries and donate 25 kg of transplant drug tacrolimus to a U.S. strategic reserve.
Kyowa Kirin
Japan's Kyowa Kirin 4151.T will provide discounts to Medicaid patients and align overseas drug pricing more closely with U.S. levels in return for potential tariff relief.
CSL
Australia's CSL CSL.AX will offer discounted medicines to Medicaid patients and invest $1.5 billion in Illinois manufacturing, creating more than 1,100 jobs, in return for clarity on its exposure to U.S. drug-pricing measures and certain pharmaceutical tariffs.
BridgeBio
BridgeBio BBIO.O will broaden Medicaid access to its heart drug Attruby and reduce costs under an agreement that the company said would help it avoid future pricing mandates.
Sun Pharmaceutical
India's Sun Pharma SUN.NS will offer discounted medicines to Medicaid patients and future therapies in return for a two-year delay in potential U.S. tariffs on its innovative drugs.
UCB
Belgium's UCB UCB.BR reached an agreement to offer more balanced drug pricing and join in a Medicaid drug-pricing program, expand manufacturing investment in the United States, donate supplies of its epilepsy drug Keppra to the national stockpile.
In exchange for exemption from potential pharmaceutical tariffs and future price mandates.
BeOne Medicines
BeOne 688235.SS agreed to expand Medicaid access to its cancer medicines, invest further in U.S. manufacturing, and secure an exemption from potential pharmaceutical tariffs.
Teva
Israel's Teva TEVA.TA attended the White House event but said in a press release it was still in discussions with the administration on a potential agreement.
However, White House materials, separately, cite Teva would contribute supplies of the antibiotic metronidazole and blood pressure drug amlodipine to a U.S. government reserve of key pharmaceutical ingredients.
Alcon
Swiss' Alcon ALCC.S also reached an agreement with the Trump administration, though no specific were disclosed.
Overview of Trump drug-pricing agreements
Sept. 1 (Reuters) - U.S. President Donald Trump has struck drug-pricing deals with more than 20 pharmaceutical companies in a bid to reduce prescription costs that are often nearly three times higher than those paid by patients in other developed countries.
The first wave of deals, struck with 17 major drugmakers starting last year, included commitments to "most-favoured-nation" pricing, sales through the TrumpRx.gov platform, and U.S. investment pledges in exchange for tariff relief.
A second wave, announced late August, added agreements with nine companies offering drugs to state Medicaid programs at most-favoured-nation prices.
XLV•
